Don’t miss our recap webinar from the American Society of Clinical Oncology Annual Conference (ASCO) where we discuss the latest research and treatments for colorectal cancer patients presented during the conference. Dr. Dustin Deming, a medical oncologist and Fight CRC Medical Advisory Board Member will guide us through his findings. Dr. Deming brings a unique perspective as a researcher, oncologist and colorectal cancer survivor. In this webinar we will dive into the research and explain what it means for those living with colorectal cancer.

1. 2017 ASCO RECAP: The Latest in
Colorectal Cancer Research
Our webinar will begin shortly.
WELCOME!

2. • Speaker: Dustin Deming, MD
• Archived Webinars: FightCRC.org/webinars
• AFTER THE WEBINAR: Expect an email with links to the
material & a survey. If you fill it out, we’ll send you an “I
booty” bracelet
• Ask a question in the panel on the RIGHT SIDE of your
screen
• Follow along via Twitter – use the hashtag #CRCWebinar
Today’s Webinar:

3. Resources:

4. Disclaimer
:
The information and services provided by Fight Colorectal
Cancer are for general informational purposes only. The
information and services are not intended to be substitutes
for professional medical advice, diagnoses or treatment.
If you are ill, or suspect that you are ill, see a doctor
immediately. In an emergency, call 911 or go to the nearest
emergency room.
Fight Colorectal Cancer never recommends or endorses any
specific physicians, products or treatments for any condition.

5. Speaker:
Dustin Deming, MD, is a gastrointestinal
oncologist and colorectal cancer laboratory
researcher at the University of Wisconsin Carbone
Cancer Center.
He has a subspecialty focus in the treatment of
colon, rectal and anal cancers. At the age of 31, he
was diagnosed with stage III rectal cancer, the very
disease he has dedicated to treating and advancing
therapies for.
As both a practitioner, researcher AND a patient, he
knows first-hand what the cancer journey is like; he
aims his research to fundamentally change the way
in which we treat gastrointestinal cancers to amore
personalized approach.

6. ASCO Update 2017:
Colorectal Cancer
Dustin Deming, MD
McArdle Laboratory for Cancer Research
Carbone Cancer Center
University of Wisconsin
6/23/2017

7. Outline
• Metastatic Cancer: Advances in Immunotherapy
• Metastatic Cancer: Advances in Precision Medicine
• Adjuvant Chemotherapy: 3 vs 6 months
• Survivorship Care

8. Metastatic Cancer: Advances in
Immunotherapy
• Nivolumab and Ipilimumab for MSI-H CRC
• CEA-TCB Bispecific Antibody
• Versican Proteolysis as a New Immune Biomarker

9. Combination of nivolumab (nivo) + ipilimumab (ipi)
in the treatment of patients (pts) with deficient
DNA mismatch repair (dMMR)/high microsatellite
instability (MSI-H) metastatic colorectal cancer
(mCRC): CheckMate 142 study.
Presented by: Thierry Andre, MD

10. Nivolumab and Ipilimumab for
MMR deficient cancers

11. Nivolumab and Ipilimumab for
MMR deficient cancers

12. Nivolumab and Ipilimumab for
MMR deficient cancers

13. Nivolumab and Ipilimumab for
MMR deficient cancers

14. CEA-TCB Antibody

15. Safety profile of CEA-TCB was manageable as monotherapy and <br />in combination with atezolizumab
Presented By Josep Tabernero at 2017 ASCO Annual Meeting

16. CEA-TCB at doses of ≥ 60 mga demonstrated clinical activity in mCRC as monotherapy and in combination with atezolizumab
Presented By Josep Tabernero at 2017 ASCO Annual Meeting

17. CEA-TCB at doses ≥ 60 mg + atezolizumab demonstrated enhanced clinical activity vs monotherapy in mCRC
Presented By Josep Tabernero at 2017 ASCO Annual Meeting

18. CEA-TCB at doses ≥ 60 mg + atezolizumab demonstrated promising clinical activity in 3L+ patients with MSS mCRC
Presented By Josep Tabernero at 2017 ASCO Annual Meeting

19. Versican Proteolysis
• A new biomarker for immune infiltration in
colorectal cancers

20. Interaction Between Cancer Genomics
and the Tumor Microenvironment
Dr. Fotis Asimakopoulos

21. VCAN Proteolysis Correlates with
CD8+ T-Cell Infiltration

22. Metastatic Cancer: Advances in
Precision Medicine
• Cetuximab, Vemurafenib and Irinotecan for BRAF
mutant cancers

23. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)
Presented By Scott Kopetz at 2017 ASCO Annual Meeting

24. Introduction
Presented By Scott Kopetz at 2017 ASCO Annual Meeting

25. Study Design
Presented By Scott Kopetz at 2017 ASCO Annual Meeting

26. Grade 3/4 Adverse Events
Presented By Scott Kopetz at 2017 ASCO Annual Meeting

27. Primary Endpoint: Progression-free survival
Presented By Scott Kopetz at 2017 ASCO Annual Meeting

28. Response Rate
Presented By Scott Kopetz at 2017 ASCO Annual Meeting

29. Subgroup Analyses
Presented By Scott Kopetz at 2017 ASCO Annual Meeting

30. Secondary Endpoint: Overall Survival
Presented By Scott Kopetz at 2017 ASCO Annual Meeting

31. Adjuvant Chemotherapy for Stage
III Colon Cancer:
3 vs 6 months duration

32. Prospective Pooled Analysis of Six Phase III Trials Investigating Duration of Adjuvant Oxaliplatin-based therapy (3 vs. 6 months) for Patients with Stage III Colon Cancer: <br
/>The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration
Presented By Qian Shi at 2017 ASCO Annual Meeting

33. Study Schema
Presented By Qian Shi at 2017 ASCO Annual Meeting

34. IDEA Trials Summary
Presented By Qian Shi at 2017 ASCO Annual Meeting

35. Adverse Events
Presented By Qian Shi at 2017 ASCO Annual Meeting

36. Primary DFS Analysis (mITT)
Presented By Qian Shi at 2017 ASCO Annual Meeting

37. Primary DFS Analysis (mITT), cont.
Presented By Qian Shi at 2017 ASCO Annual Meeting

38. DFS Comparison by Risk Group and Regimen, cont.
Presented By Qian Shi at 2017 ASCO Annual Meeting

40. Recommendations Going Forward
Ways Oncologists are Thinking About this Data
• 6 months of adjuvant chemotherapy for everyone
• 3 months for low risk and 6 months for high risk
• Give oxaliplatin for first 3 months only, and finish
with infusional 5FU for total of 6 months
• Maybe CAPEOX is better than FOLFOX
Dusty’s Opinion
• Risk/benefit ratio approach

41. Survivorship Care
• Tree Nuts
• Vitamin D
• PET/CT scans

42. Nut Consumption and Survival in Stage III Colon Cancer Patients: Results from CALGB 89803 (Alliance)

43. CALGB 89803

44. Slide 13

45. Results

46. Some preclinical rationale

47. Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy: NCCTG N0147 (Alliance)

48. Vitamin D by Tertile with Outcome

49. Secondary analyses of 89803

50. What do I do or at least try to do?
• Aspirin – 81-325mg per day
• Exercise – Half hour of moderate exercise more
days than not
• Multi-vitamin
• Low glycemic index diet
• Coffee
• Tree nuts or tree nut products

51. Question & Answer:
SNAP A
#STRONGARMSELFIE
Bayer HealthCare will donate $1 for every
photo posted (up to $25,000).
Flex a “strong arm” & post it to Twitter or
Instagram! (Use the hashtag!)

52. Contact Us!